BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25056361)

  • 21. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.
    Chowdhury MI; Sheikh A; Qadri F
    Expert Rev Vaccines; 2009 Dec; 8(12):1643-52. PubMed ID: 19943759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
    Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
    Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.
    Leung DT; Rahman MA; Mohasin M; Patel SM; Aktar A; Khanam F; Uddin T; Riyadh MA; Saha A; Alam MM; Chowdhury F; Khan AI; Charles R; LaRocque R; Harris JB; Calderwood SB; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2012 May; 19(5):690-8. PubMed ID: 22441386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea.
    Ahmed T; Bhuiyan TR; Zaman K; Sinclair D; Qadri F
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD009029. PubMed ID: 23828581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.
    Trach DD; Cam PD; Ke NT; Rao MR; Dinh D; Hang PV; Hung NV; Canh DG; Thiem VD; Naficy A; Ivanoff B; Svennerholm AM; Holmgren J; Clemens JD
    Bull World Health Organ; 2002; 80(1):2-8. PubMed ID: 11884967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru.
    Taylor DN; Cárdenas V; Sanchez JL; Bégué RE; Gilman R; Bautista C; Perez J; Puga R; Gaillour A; Meza R; Echeverria P; Sadoff J
    J Infect Dis; 2000 May; 181(5):1667-73. PubMed ID: 10823767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.
    Desai SN; Akalu Z; Teshome S; Teferi M; Yamuah L; Kim DR; Yang JS; Hussein J; Park JY; Jang MS; Mesganaw C; Taye H; Beyene D; Bedru A; Singh AP; Wierzba TF; Aseffa A
    Am J Trop Med Hyg; 2015 Sep; 93(3):527-533. PubMed ID: 26078323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral vaccines for preventing cholera.
    Sinclair D; Abba K; Zaman K; Qadri F; Graves PM
    Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD008603. PubMed ID: 21412922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected).
    Graves PM; Deeks JJ; Demicheli V; Jefferson T
    Cochrane Database Syst Rev; 2010 Aug; 2010(8):CD000974. PubMed ID: 20687062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model.
    Kang SS; Yang JS; Kim KW; Yun CH; Holmgren J; Czerkinsky C; Han SH
    Mucosal Immunol; 2013 Jul; 6(4):826-37. PubMed ID: 23187318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral vaccines against cholera: lessons from Vietnam and elsewhere.
    Levine MM
    Lancet; 1997 Jan; 349(9047):220-1. PubMed ID: 9014902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholera vaccine: new preventive tool for endemic countries.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2012 May; 8(5):682-4. PubMed ID: 22634452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
    Chowdhury F; Akter A; Bhuiyan TR; Tauheed I; Teshome S; Sil A; Park JY; Chon Y; Ferdous J; Basher SR; Ahmed F; Karim M; Ahasan MM; Mia MR; Masud MMI; Khan AW; Billah M; Nahar Z; Khan I; Ross AG; Kim DR; Ashik MMR; Digilio L; Lynch J; Excler JL; Clemens JD; Qadri F
    Vaccine; 2022 Jan; 40(4):640-649. PubMed ID: 34969541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.
    Leung DT; Uddin T; Xu P; Aktar A; Johnson RA; Rahman MA; Alam MM; Bufano MK; Eckhoff G; Wu-Freeman Y; Yu Y; Sultana T; Khanam F; Saha A; Chowdhury F; Khan AI; Charles RC; Larocque RC; Harris JB; Calderwood SB; Kovác P; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2013 Jun; 20(6):780-8. PubMed ID: 23515016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.
    Black RE; Levine MM; Clements ML; Young CR; Svennerholm AM; Holmgren J
    Infect Immun; 1987 May; 55(5):1116-20. PubMed ID: 3552989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of O-specific polysaccharide responses in patients following infection with
    Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
    mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area in Bangladeshi children.
    Saha A; Chowdhury MI; Nazim M; Alam MM; Ahmed T; Hossain MB; Hore SK; Sultana GN; Svennerholm AM; Qadri F
    Vaccine; 2013 Jan; 31(4):647-52. PubMed ID: 23200936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Live oral vaccines against cholera: an update.
    Levine MM; Kaper JB
    Vaccine; 1993; 11(2):207-12. PubMed ID: 8438619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.